# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k063610   
B. Purpose for Submission: This is a new device.   
C. Measurand: Human ${ \bf { \alpha } } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ }$ – antitrypsin   
D. Type of Test: Quantitative immunonephelometry   
E. Applicant: Dade Behring Inc.   
F. Proprietary and Established Names: Dimension VISTA™ ${ \bf { \alpha } } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ }$ – antitrypsin Flex $^ \mathrm { \textregistered }$ reagent cartridge (A1AT) Dimension VISTA™ Protein 1 Calibrator Dimension VISTA™ Protein 1 Control L Dimension VISTA™ Protein 1 Control M Dimension VISTA™ Protein 1 Control H

# G. Regulatory Information:

1. Regulation section: 21CFR $\ S$ 866.5130, Alpha-1-antitrypsin Immunological Test System. 21CFR $\ S$ 862.1660, Quality Control Material (Assayed and Unassayed) 21CFR $\ S$ 862.1150, Calibrator   
2. Classification: Device and calibrator - Class II Quality control material - Class I   
1. Product code: DEM, Alpha-1-antitrypsin, Antigen, Antiserum, Control JJY, Multi- Analyte Controls (Assayed and Unassayed) JIX, Calibrator, Multi-Analyte Mixture   
4. Panel: Immunology (82) Chemistry (75)

# H. Intended Use:

1. Intended use(s):

# Dimension $V I S T A ^ { \mathbf { T M } } \mathbf { G } _ { 1 }$ – antitrypsin $\mathbf { F l e x } ( \mathbf { \widehat { R } } )$ reagent cartridge (A1AT)

The A1AT method is an in vitro diagnostic test for the quantitative determination of alpha-1-antitrypsin in human serum, heparinized plasma or EDTA plasma on the Dimension VISTA™ system. Measurements of alpha1-antitrypsin aid in the diagnosis of adult cirrhosis of the liver and pulmonary emphysema.

# Dimension VISTA™ Protein 1 Calibrator:

PROT1 CAL is an in vitro diagnostic product for the calibration of the $\mathtt { a } _ { 1 } -$ antitrypsin (A1AT), C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), and Prealbumin (PREALB) methods on the Dimension VISTA™ system.

# Dimension VISTA™ Protein 1 Control L, M and H

PROT1 CON L, M and H are assayed intralaboratory quality controls for assessment of precision and analytical bias in the determination of the ${ \tt d } _ { 1 } -$ antitrypsin (A1AT), C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), and Prealbumin (PREALB) on the Dimension VISTA™ system.

2. Indication(s) for use: Same as above   
3. Special conditions for use statement(s): For prescription use only.   
4. Special instrument requirements: For use in the Dimension VISTA™ system (k051087)

# I. Device Description:

The Dimension $\mathrm { V I S T A ^ { T M } G _ { 1 } } .$ – antitrypsin Flex $^ \mathrm { \textregistered }$ reagent cartridge (A1AT) consists of N antiserum to human ${ \bf { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { \alpha } \mathrm { } \mathrm \mathrm { \alpha } \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \mathrm \alpha } \mathrm \mathrm  \mathrm { \alpha } \mathrm \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm  \mathrm \alpha \mathrm \mathrm { } \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \alpha \mathrm \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm $ – antitrypsin, and reaction buffer with phosphate buffer and polyethylene glycol. All reagents are liquid and ready to use.

PROT1 CAL is a multi-analyte, liquid, human serum based product containing ${ \bf { \alpha } } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ }$ – antitrypsin (A1AT), C3 Complement (C3), C4 Complement (C4),   
Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), and Prealbumin (PREALB).   
PROT1 CAL is ready for use.

Dimension VISTA™ Protein 1 Control L,M and H are multi-analyte; liquid human serum-based products containing ${ \bf { \alpha } } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ }$ – antitrypsin (A1AT), C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), and Prealbumin (PREALB). The controls are ready for use.

The other analytes in the calibrator and controls were cleared under the following premarket notifications: C3 and C4 (k061852), IgA (k061338), IgG (k051087), IgM (k061845) and Prealbumin (k062055)

The controls and calibrator are sold separately.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dade Behring N Antisera to Human ${ \bf { \alpha } } _ { \bf { { \alpha } } } \mathrm { ~  ~ \Omega ~ }$ –antitrypsin assay N Protein Standard SL

N/T Protein Control SL   
2. Predicate 510(k) number(s): k053072 k012470 k012468   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Dimension VISTATMα1 -antitrypsin Flex® reagent</td><td rowspan=1 colspan=1>N Antisera to α1 -antitrypsin</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Aid in the diagnosis ofadult cirrhosis of the liverand pulmonaryemphysema in conjunctionwith other clinical andlaboratory findings.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Nephelometry</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage conditions</td><td rowspan=1 colspan=1>Refrigerate at 2-8°C untilexpired</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Traceable to ERM®DA470</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Rabbit polyclonal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>human serum, heparinizedplasma or EDTA plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Components</td><td rowspan=1 colspan=1>Controls and standards aresold separately.</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Analyzer</td><td colspan="1" rowspan="1">Dimension VISTATMsystem.</td><td colspan="1" rowspan="1">BNTM Systems</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">DimensionVISTATMPROT1 CAL</td><td colspan="1" rowspan="1">N Protein Standard SL</td></tr><tr><td colspan="1" rowspan="1">Calibrator constituents</td><td colspan="1" rowspan="1">A1AT, C3, C4, IgA,IgG, IgM andprealbumin</td><td colspan="1" rowspan="1">IgG, IgG1, IgG2, IgG3,IgG4, IgA, IgM, albumin,A1AT, α2-macroglobulin,αacid glycoprotein,haptoglobin, prealbumin,hemopexin,ceruloplasmin, retinolbinding protein, Ig light-kappa, Ig light-chainLambda, solubletransferrin receptor,</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ferritin, β2-microglobulinand total protein</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Dimension VISTATMPROT1Control L, Mand H</td><td colspan="1" rowspan="1">N/T Protein control SL L,M and H</td></tr><tr><td colspan="1" rowspan="1">Control constituents</td><td colspan="1" rowspan="1">A1AT, C3, C4, IgA,IgG, IgM andprealbumin</td><td colspan="1" rowspan="1">IgG, IgG1, IgG2, IgG3,IgG4, IgA, IgM, albumin,A1AT, α2-macroglobulin,αacid glycoprotein,haptoglobin, prealbumin,hemopexin,ceruloplasmin, retinolbinding protein, Ig Light-kappa, Ig Light-chainLambda, solubletransferrin receptor,ferritin, β2-microglobulinand total protein</td></tr><tr><td colspan="1" rowspan="1">Reportable range</td><td colspan="1" rowspan="1">0.17-5.20 g/L</td><td colspan="1" rowspan="1">0.16-5.20 g/L</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Approved Guideline for Evaluation of Precision Performance of Clinical   
Devices: EP5-A2   
CLSI EP7-A, Interference testing in Clinical Chemistry

L. Test Principle:

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision testing was done in accordance with CLSI Approved Guideline for Evaluation of Precision Performance of Clinical Devices: EP5-A. Specimens with concentrations close to the reportable range were analyzed in duplicate, twice a day, for 20 days. The within-run and total standard deviations (SD) and percent coefficient of variation $( \% C V )$ were calculated by the analysis of variance method. The data are summarized below

<table><tr><td rowspan=2 colspan=1>Material</td><td rowspan=2 colspan=1>Mean(g/L)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-lab</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>PROT1 Con L</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.36</td></tr><tr><td rowspan=1 colspan=1>PROT1 Con M</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.09</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.27</td></tr><tr><td rowspan=1 colspan=1>PROT1Con H</td><td rowspan=1 colspan=1>2.21</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.20</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>2.68</td></tr><tr><td rowspan=1 colspan=1>Serumpool</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.74</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>3.61</td></tr><tr><td rowspan=1 colspan=1>Serum pool</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>2.28</td></tr><tr><td rowspan=1 colspan=1>Plasma pool</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.80</td></tr></table>

# b. Linearity/assay reportable range:

Linearity testing was performed on the Dimension VISTA $^ \mathrm { \textregistered }$ System by testing a calibrator with a concentration of $1 . 4 8 \ \mathrm { g / L } \ \alpha _ { 1 } $ – antitrypsin. The calibrator was serially diluted with system diluent at the following six dilutions 1:3.8, 1:8, 1:20, 1:40, 1:90 and 1:200. Each dilution was tested in replicates of three and a median is calculated. Data was analyzed using linear regression analysis (x-axis: theoretical concentration and yaxis: measured concentration). The acceptance criteria of slope between 0.9 and 1.1 and correlation coefficient ${ \ge } 0 . 9 5$ were met. Data showed a regression equation $\mathbf { y } = 1 . 0 1 9 \mathbf { x } - 0 . 0 2 9 , \mathbf { r } ^ { 2 }$ of 1.00.

Additional linearity study for the Vista A1AT assay was performed by testing a serum sample with a high concentration of A1AT. The sample was serially diluted with system diluent down to the lower measuring range (4.52 to $0 . 2 2 { \ \mathrm { g / L } }$ ). Each dilution was tested in replicates of five. Data was analyzed using linear regression analysis (x-axis: theoretical concentration and y-axis: measured concentration). The acceptance criteria of slope between 0.9 and 1.1 and correlation coefficient ${ \ge } 0 . 9 5$ were met. Data showed a regression equation $\mathrm { y } = 1 . 0 1 5 \mathrm { x } - 0 . 0 4 3 , \mathrm { r } ^ { 2 }$ of 0.99.

Linearity was observed at 0.15 to $7 . 9 7 8 \mathrm { g / L }$ . Reportable range for the device was set at 0.17 to $5 . 2 0 \ \mathrm { g / L }$

# Prozone effect

The possibility of Prozone effect occurring when using the device was evaluated with a serum sample above the assay range $( 1 0 . 2 \ \mathrm { g / L } )$ . The sample was analyzed on both the BN Prospec System and the Dimension Vista instrument, indicating no hook effect up to $1 1 . 0 3 \ : \mathrm { g / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The reference material is the ERM $^ \mathrm { \textregistered }$ -DA470 (CRM 470). Master Calibrator and Master Control concentrated human serum pool were assayed against this reference material. Commercial Calibrator and Control Lots were prepared from human serum pool at target concentrations and assayed against the master lot. Three reference curves, 4 runs, 3 vials, 4 replicates per vial tested on two instruments for a total of 144 values were used before release of shipment.

Stability studies were performed and the following conclusions were obtained:

On-Board Instrument Stability of opened product: a. The Dimension $\mathrm { V I S T A ^ { T M } G _ { 1 } } .$ – antitrypsin Flex $^ \mathrm { \textregistered }$ reagent cartridge is stable on –board the instrument for 21 days. b. PROT1 CAL is stable for 9 days. c. Controls are stable for 9 days.

Study duration is 24 months. Product is stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ throughout the testing cycle and tested on day 0 and after 12, 18, and 24 months.

Sealed reagent cartridge on board instrument is stable up to 90   
days.   
Open Punctured well: a. Once the vial stopper is punctured, assigned values of PROT1 CAL and PROT1 Con L, M and H is stable for 9 days.

d. Detection limit:

The analytical sensitivity of the assay represents the lowest concentration of analyte that can be distinguished from zero. The value was calculated as the mean value $( \mathrm { n } { = } 2 0 )$ ) of System diluent plus two standard deviations. This was found to be $0 . 0 1 6 \ : \mathrm { g / L }$ .

e. Analytical specificity:

Interference: Interference testing was performed using guidance supplied by CLSI EP7-A, “Interference testing in Clinical Chemistry”. No significant interference was observed in:

Hemoglobin up to $1 0 0 0 \mathrm { m g / d L }$ • Bilirubin (conjugated and unconjugated) up to $6 0 \mathrm { m g / d L }$ • Triglycerides up to $6 3 7 \mathrm { m g / d L }$ • Immunoglobulin G up to $5 0 0 0 \mathrm { m g / d L }$ • Protein: Albumin up to $6 0 0 0 \mathrm { m g / d L }$ • Urea up to $5 0 0 \mathrm { m g / d L }$ $\bullet$ Cholesterol up to $5 0 0 \mathrm { m g / d L }$ • Creatinine up tog/dL • Uric acid up to $2 0 \mathrm { m g / d L }$

Non Interfering Substance section of the package insert provides a list of drugs and other exogenous substances that do not interfere with the assay.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: The table below shows the comparison of 66 serum samples and 73 plasma samples ranging from 0.23 to $4 . 7 1 \ \mathrm { g } \ / \mathrm { L }$ that were tested with the Dimension Vista™ ${ \bf { \alpha } } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ } \mathrm { ~  ~ \alpha ~ }$ – antitrypsin Flex $^ \mathrm { \textregistered }$ reagent cartridge (A1AT) and the predicate device Dade Behring $_ \mathrm { N }$ Antisera to Human ${ \bf { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { { \alpha } } \mathrm \mathrm { \alpha } \mathrm { } \mathrm \mathrm { \alpha } \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm { \mathrm \alpha } \mathrm \mathrm  \mathrm { \alpha } \mathrm \mathrm \mathrm { \alpha } \mathrm \mathrm { \alpha } \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm  \mathrm \alpha \mathrm \mathrm { } \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm { \alpha \alpha } \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \alpha \mathrm \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \alpha \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm  \mathrm \mathrm \mathrm \mathrm \mathrm \mathrm $ – antitrypsin assay. No information about age and gender was provided. The results were summarized below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Dimension Vistavs. BN system(Dade-Behring)</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.000(95%CI: 0.9853 to 1.0283)</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>0.070 (95%CI:0.0346 to 0.0938)</td></tr><tr><td rowspan=1 colspan=1>Range (g/L)</td><td rowspan=1 colspan=1>0.23to4.71g /L</td></tr><tr><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>0.996</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>139</td></tr></table>

b. Matrix comparison:

Matrix comparison studies using matched serum, EDTA, lithium and sodium heparinized plasma samples covering the measuring range were performed on the Dimension Vista™ ${ \tt Q } _ { 1 }$ – antitrypsin Flex $^ \mathrm { \textregistered }$ assay. The results of the linear regression analyses are seen on the table below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>CorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>Serum vs.Lithium Heparin</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1.0(0.968-1.02)</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Serum vs.Sodium Heparin</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1.03(1.008-1.05)</td><td rowspan=1 colspan=1>-0.02</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Serum vs. EDTA</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.99(0.976-1.00)</td><td rowspan=1 colspan=1>-0.01</td><td rowspan=1 colspan=1>1.00</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The reported expected range for Immunoglobulin A in adults $( 0 . 9 - 2 . 0 \ : \mathrm { g / L } )$ is from a literature (Dati F. Schumann G,Thomas L, et al. Consensus of a Group of Professional Societies and Diagnostic Companies on Guidelines for Interim Reference Ranges for 14 Proteins in Serum base on the Standardization against the IFCC/BCR/CAP Reference Material (CRM 470). Eur J Clin Chem Biochem 34:517-520, 1996).

Each laboratory should establish its own normal ranges since values may differ depending on the population studied.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.